On August 21, GIANT BIOGENE fell 5.14% in regular trading, trading at HK$28.04/share, with turnover of HK$57.61 million.
On the news front, China Merchants Securities downgraded the stock from Hold to Sell with a target price of HK$25, significantly below the current share price. The bearish call stands in stark contrast to recent buy ratings from Citi, Dongwu Securities, and Guojin Securities, creating a notable divergence among institutional views and weighing on market sentiment.
The downgrade comes after the company reported interim results on August 18, showing revenue of RMB 2.918 billion, down 6.3% year-over-year, and net profit attributable to equity holders of RMB 940 million, down 20.5%. Core brand Collgene underperformed while selling expenses surged nearly 20%. Following a nearly 5% rebound in the prior session driven by bullish broker calls, the fresh sell rating renewed selling pressure. Citi had raised its target to HK$38.4 and designated the stock as its top pick in China cosmetics, while the FactSet consensus mean target remains at HK$37.14.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments